DrFirst Backline™ ensures that care team members are equipped with seamless, efficient, real-time communication tools around the clock at any point-of-care

SANTA CLARA, California, May 2, 2019 /PRNewswire/ — Based on its recent analysis of the North American market for secure text messaging for care collaboration, Frost & Sullivan recognized DrFirst,the nation’s leading provider of e-prescribing, medication management, and price transparency management solutions,with the 2019 North American Enabling Technology Leadership Award for its Backline secure collaboration solution. It is a HIPAA compliant, feature-rich, chat and texting application that is purpose-built for healthcare. The solution is offered as a stand-alone mobile app and is also available for desktops, which is particularly valuable for information sharing and communication with administrative staff.

DrFirst, Inc.

“Backline allows users to create secure one-on-one or group chats easily as well as to deliver push message notifications. Users can view availability and message status indicators including read receipts, acknowledgments, and timestamps, and can send and share multiple types of content including up to 20MB of photos, lab results, and audio or video files for better care collaboration and to support more efficient prior authorizations,” said Mike Jude, Research Manager of Digital Health. “Furthermore, DrFirst Backline is integrated with the West-Com nurse call system and has a call center module for case management, which is unique in the industry.”

As the only mobile care coordination solution to feature patient-centered chat, Backline helps patient care team members collaborate and share patient-specific data immediately, inside or outside a facility. This feature offers significant value to DrFirst customers as it ensures true patient-centric care. Secure text messaging makes it easier to communicate with referring physicians and primary care providers, get the right medications to the right patients, view images and lab results, and even connect with the patient’s family members and caregivers. Efficient workflows lead to better care team collaboration and improved patient outcomes.

DrFirst is exceptional in its ability to leverage a vast partner network for robust health information exchange among trusted patient care participants across its solution set and throughout healthcare. This network includes more than 220,000 healthcare professionals and 75,000 prescribers as well as thousands of  acute care facilities, pharmacies, and ambulatory care facilities. , and hundreds of EHR/HIS vendors. . It gives healthcare professionals real-time access to crucial clinical information at the point-of-care and the means to perform a range of essential communication tasks to ensure the highest level of patient care and safety.

“Significantly, DrFirst Backline and other DrFirst solutions can help providers meet myriad new requirements for value-based care and potentially qualify for government-based financial quality incentive programs such as MACRA/MIPS,” noted Jude. “Industry adoption of the platform has grown 1,000 fold in the last three years due to its adoption in all segments of the provider market, particularly the hospice and long-term care segments. Its security and strong value proposition for both patients and caregivers has positioned it for remarkable growth.”

“We are delighted to be recognized by Frost & Sullivan for this prestigious award,” said G. Cameron Deemer, president of DrFirst. “We are focused on bringing together all participants in the healthcare ecosystem to bring a new level of communication, quality, and outcomes to patient care. This award is validation that we continue to lead the industry in effective and efficient care collaboration technology.”

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that not only enhances current products but also enables the development of new products and applications. The award recognizes the high market acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About DrFirst
DrFirst, the nation’s leading provider of e-prescribing, price transparency, and medication management solutions enables stakeholders across the healthcare industry to use comprehensive real-time data and connectivity to increase patient safety ratings, efficiency, and profitability. Today, more than 220,000 healthcare professionals, 75,000 prescribers, and hundreds of electronic health record (EHR) vendors depend on DrFirst’s innovative software solutions to improve clinical workflows, expedite secure collaboration across a patient’s care team and drive better health outcomes. The company’s integrated technologies include its award-winning electronic prescribing platform, the most comprehensive medication history available, clinically specialized secure messaging, and patient medication adherence monitoring and benefits checking. In addition, DrFirst was the first to offer e-prescribing for controlled substances (EPCS) and is considered the industry standard for providers nationwide. For more information, please visit www.drfirst.com or connect with us @DrFirst.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:
Kristen Moore
P: 210.247.3823
E: kristen.moore@frost.com

Photo – https://mma.prnewswire.com/media/880533/DrFirst__Inc__Award.jpg

BOSTON, April 29, 2019 /PRNewswire/ — On April 28, the “2019 China Nanjing Tech Week in Boston” series of events were held in Boston, USA. It was organized by Nanjing Innovation City Promotion Center (NPO) and sponsored by Nanjing Jiangbei New Area Management Committee. Attendees included the Consul of Science and Technology, Consulate General of China in New York, the Executive Director of Department of Commerce and Investment, Massachusetts, representative of Boston Government, representatives of universities and colleges, representatives of relevant institutions and enterprises located in Boston.

The Nanjing-Boston Twin Cities Summit Forum opened on the morning of April 28. In total, more than 80 people attended this Forum, including Mr. Feng Hu, a Consul of Science and Technology, Consulate General of China in New York; Mr. Mark F. Sullivan, the Executive Director, Department of Commerce and Investment, Massachusetts; Mr. Ed Flynn, a Councilor of Boston, and others. Experts included Prof. J. Michael Ramsey, a professor of University of North Carolina and an academician of National Academy of Engineering, and Mr. Zhou Jinrong, a professor of Harvard Medical School. Additionally, Chen Chanmei, Deputy Director of Nanjing Jiangbei New Area Management Committee, and representatives of relevant institutions such as Boston Research Institute, The Consul of Science and Technology, Consulate General of China in New York, the Executive Director of Department of Commerce and Investment, Massachusetts, and the representative of Boston Government all delivered speeches respectively. Mr. Mark F. Sullivan, the Executive Director, Department of Commerce and Investment, Massachusetts, highly affirmed the existing environment, resource superiority, and policy of Jiangbei New Area, and was full of confidence in the communication and cooperation with Jiangbei New Area.

The Forum also included the unveiling ceremony of the Nanjing Overseas Cooperative Innovation Center, which was established by Nanjing. It will serve as a foreign communication window in a region with the most active innovation globally. Nanjing Overseas Cooperative Innovation Center, established in Boston, will build a bridge between Boston and Nanjing and Jiangbei New Area in the fields of science and technology, history and culture, capital and market, and boost the exchange, communication, and win-win cooperation between the USA and China.

Talents are indispensable for innovation and development. In order to gather Nanjing’s elite talents from each field in Boston, promote Nanjing and Boston to strengthen cooperation, and improve the industrial research and development ability of Nanjing, Nanjing Alumni Association (Boston Area) Alliance was established on that very evening. Mr. Pan Ye, President of Southeast University Alumni in Boston Area, alumni representatives of Nanjing University, and other distinguished guests attended this establishment ceremony.

With the background that Nanjing deepens and promotes the construction of “Famous Innovation City, Beautiful Ancient Capital”, Nanjing Municipal Committee and Municipal Government have decided to hold Nanjing Tech Week on June 28, 2019. As introduced by Nanjing Tech Week Organizing Committee, representatives from the 15 high-tech zones in Nanjing will successively visit 23 overseas countries and regions, gather the worlds most advanced innovation resources for Nanjing, conclude “innovation community” with more international innovation cities, innovation institutions, and innovation talents, and accelerate the construction of a famous innovation city with global influences.

Boston is an international benchmark city for Nanjing to construct the “Famous Innovation City, Beautiful Ancient Capital”, and it is the place with the densest advanced technology and the greatest innovation ability in the world. There are more than 100 universities in Boston including Harvard University, Massachusetts Institute of Technology, and others. The city also boasts the thriving hospital industry cluster, Longwood Medical and Academic Area, where more than 100 biotechnology companies have gathered. Also, Boston is the third largest financial center of the USA, and the fourth largest financial center of North America. Further accelerating the promotion of the bilateral cooperation in each field like talent training, scientific research innovation, financial capital and market promotion, and others will also push forward and promote the formation and development of both parties’ innovative economic clusters.

View original content:http://www.prnewswire.com/news-releases/the-2019-china-nanjing-tech-week-in-boston-series-of-events-held-in-boston-300839781.html

TAIZHOU, China, April 26, 2019 /PRNewswire/ — In the preliminary meeting of operating the regional research center, International Centre for Genetic Engineering Biotechnology (ICGEB) in China, Science and Technology Daily was informed that China Medical City (CMC), China’s leading medical industrialization base in Taizhou, Jiangsu Province, was invited by ICGEB to discuss the promotion and collaboration between CMC and ICGEB.

The meeting mainly discussed which areas of research activities will be the most appropriate for collaboration. “In cooperation with CMC, we are expecting there will be novel approaches for the development of new therapeutics, vaccines, and diagnostics,” Dr. Lawrence Banks, the scientific coordinator and group leader of ICGEB, told Science and Technology Daily recently.

ICGEB is an international institution promoted by the United Nations Industrial Development Organization. As a center of excellence for research and training in genetic engineering and biotechnology, its goal is to make benefits for the developing countries.

Collaborating with CMC and China National Center for Biotechnology Development (CNCBD), ICGEB decided to set up the worlds first ICGEB regional research center (ICGEB-RRC) at CMC. Through providing high-quality research fields, holding meetings and workshops, training scientists in the lab and providing great opportunities in ICGEB-RRC, top-class scientists will be attracted to do research and tackle disease here. Banks told Science and Technology Daily that within the CMC, ICGEB will find ways to improve local advantages.

Although CMC invests more in developing biotechnology, there is a long way to go for the future development. Take ICGEB-RRC as an example, Banks gave his suggestions. The main advice is to push science innovation, as big discoveries can greatly impact the global health sector. 

Banks mentioned the importance of promoting collaboration and building networks around the world for the future development of biological research as well. He explained that inviting experts from different regions to the ICGEB-RRC and finding the most appropriate ways through discussions could provide a better way to promote local biotech development.

CMC will hold the China International Medical Expo 2019 (MedicalExpo), one of the most famous world-wide medical exhibitions in China in September, and it will reach its ten-year milestone.

Last year, 230 foreign enterprises from 30 different countries took part in the MedicalExpo and brought lots of new biotechnologies, equipments and research results.

View original content:http://www.prnewswire.com/news-releases/new-research-partnership-brings-top-class-scientists-to-china-to-tackle-biomedical-problems-300838967.html

BEIJING, April 26, 2019 /PRNewswire/ — QTC Care has announced the close of around 7 million USD series-A financing. It is a health care company focusing on introducing the world’s top medical resources to the Chinese market and utilizes artificial intelligence to streamline treatment recovery and disease prevention. The investment was led by a Chinese internet giant, Tencent, followed by several other top investors in China. This funding will be primarily used for the development of Digital Therapeutics (DTx) and building medical network to service insurance companies.

Lu Yi, CEO of QTC Care said: “Traditional health and disease management is usually half-baked due to the lack of effective incentive mechanism and human-based management. Our solution — Digital Therapeutics (DTx), and other health management services, uses a combination of artificial intelligence and social interaction, a huge step towards helping treatment recovery, chronic disease management, and disease prevention. We are grateful for our investor and partners in supporting our work.”

Two types of Digital Therapeutics (DTx) have gone live now. “Micha initiative-weight-loss DTx”, based on advanced scientific weight-loss concepts, has successfully helped participants to lose 4kg of weight on average within 3 weeks, an equivalent of 54% less risk in chronic and major diseases through online behavioral intervention. Another DTx, “kapok”, can help cancer patients to improve their life quality, reduce total medical costs, and number of visits to ER through similar behavioral intervention.

Meanwhile, QTC Care has developed out-of-hospital patient health management platforms. Taking the two platforms for lung cancer patients and breast cancer patients for example, so far, they have accrued tens of thousands of users, and according to the latest statistics among those users, 100% patients said their knowledge about the disease improved, 87.1% felt they better understood their treatment plan, 96.77% improved their ways to cope with adverse events, patients who took their medication on time has improved from 57.9% to 75.9%, and the ratio of on-time follow-up has improved from 73.68% to 87.1%. Another “Cancer patients’ family members” assistance and care project is also up and running to provide guidance to family members in cancer patients’ care.

QTC Care core team has been concentrating on bringing the world’s best quality oncology medical resources to China since 2013, and has independently developed the remote video consultation system, first of its kind in China. Now it boasts resources of cooperation with more than 600 internationally renowned hospitals and connections with thousands of world top doctors. It is committed to providing patient-oriented medical services, allowing patients to seek high-quality medical treatment with dignity.

In addition, QTC Care leveraged in health care insurance market as preferred Third Party Administration (TPA) in 2018. We have successfully developed a few products with multiple leading insurance companies in Greater China and will be dedicated in this industry.

Data Reference: American Diabetes Association

View original content:http://www.prnewswire.com/news-releases/qtc-care-closes-7-million-usd-series-a-financing—focusing-on-introducing-global-top-medical-resources-to-china-and-advancing-health-management-platforms-300839015.html

BANGKOK, April 26, 2019 /PRNewswire/ — Health and religious authorities in Thailand lead a campaign to raise awareness on skyrocketing obesity among monks and urge Buddhist devotees to be mindful of the food they prepare for them.

“Making Merit or Creating Hurt”

To help Buddhists learn about this silent threat to the monks, Thailand’s Priest Hospital (Buddhist Monk Hospital), in collaboration with Baramee Dhamma Hall Foundation and Ogilvy Thailand, has created the “Making Merit or Creating Hurt” campaign to promote a leaner, healthier clerical living by protecting the monks from unhealthy foods through public displays of sculptural art.

This campaign launched in the first week of April, when sculptures of healthy, lean monks were found at temples, marketplaces, hospitals and meditation retreats across Bangkok, Thailand. Then, when the public returned to the same spots two weeks later during Songkran holiday, a national holiday during which Buddhists gather at temples to celebrate the Thai New Year by making merits and offering food to monks, the display changed to a miserable-looking, obese monk suffering from diabetic wounds on the foot.

An MMS containing information about the campaign was sent to individuals in close proximity to the sculpture exhibition via a location-based service. The campaign’s website, www.obesitymonk.com, was also included in the message to provide receivers with more details as well as nutritious food recipes which are applicable to Buddhist monks’ diet.

The tradition of Buddhism has been rooted in Thailand and the majority of Asia for over two thousand years. A large portion of Thai Buddhists, which account for 95% of the country’s population, believe that the act of donating food to monks not only grants blessings for themselves, but is also a spiritual way to share alms with their loved ones who have passed away. For many day-to-day occasions, it is common for Buddhists to prepare the deceased’s favorite foods for the alms bowl, overlooking the fact that such favored food — often laden with fat and sugar — may do more harm than good to the monks’ health.

Since these offerings largely contain high-cholesterol, highly-seasoned and fatty innutritious foods, the adverse effects would fall onto the monks who are obliged to consume them despite careful consideration. That, combined with the monastic discipline forbidding monks from rejecting food offered by the faithful, as well as the sedentary nature of temple monastic life, has resulted in approximately one-third of 300,000 Buddhist monks in Thailand suffering from extra weight and other related diseases and conditions, such as obesity, diabetes, high cholesterol, hypertension, high blood pressure, coronary heart diseases and joint problems.

“The number of sick monks in Thailand has continued to soar over the last ten years, leading to an expanding amount of medical fees of up to one billion baht for the government to cover,” said Chumni Jittreprasert, M.D, Director of Thailand’s Priest Hospital, who spearheaded the “Making Merit of Creating Hurt” campaign, “This campaign has been made to urge Buddhists to be aware of possible health woes brought upon the monks which may be exacerbated by their own hands.” 

The doctor stressed, “The incidents where monks had to have their leg amputated due to incurable diabetic infections or constantly battle chronic cholesterol-related conditions are real, and I believe any Buddhist devotee would be just as startled and upset by this fact. Now that the situation has become a major crisis, we need to solve the issue immediately and deal with the root cause of the ailments. Whether it is a home-cooked meal or a prepared dish from street vendors, the least the merit makers can do is to ensure that the edible choice they make for the monks is nutritious and healthy. To allow the monks to maintain a healthy wellbeing, Buddhists are encouraged to choose low-fat, less-sugary foods for the donation instead of deep-fried, oily, highly-seasoned and oversaturated kinds of food for them.”

Watchara Prayoonkum, the nationally acclaimed sculptor behind the “Obese Monk” statues also weighed in on the issue. He said, “As a Buddhist devotee, it appalls me to see Buddhist monks get sick and suffer. I created this set of sculptures in hope of promoting knowledge on this serious problem, and stressing how unhealthy alms giving, though unintended, can lead to such tragic results. Artistic elements of the sculpture are used to showcase intended meanings, such as severe diabetic wounds, uneven sculpted texture representing extra cellulite and gold coating representing the traditional virtue that unfortunately turns into damage to the religion. I hope these sculptural displays will open the eyes of Buddhists and remind them to be more careful when preparing food for monks.”

For more information about the “Making Merit or Creating Hurt” campaign and downloadable nutritious food recipes, please visit www.obesitymonk.com. Those who are interested can also sign the petition at http://chng.it/FnPxHNWHXR to create a social movement to improve the wellbeing of Buddhist monks in Thailand.

VDO teaser: https://www.youtube.com/watch?v=PozkZHE7GPY&feature=youtu.be

For more information, please contact

Jintana Duangkaew Ogilvy Group (Thailand)
e-mail: jintana.duangkaew@ogilvy.com
tel: +66 8 4 673 8889

Photo – https://photos.prnasia.com/prnh/20190426/2447888-1

SINGAPORE, April 26, 2019 /PRNewswire/ — BD (Becton, Dickinson and Company), a leading global medical technology company, has launched a new patient safety program for hospitals, called Preventing Risks of Infections and Medication Errors in IV Therapy (PRIME). Aimed at addressing the top two challenges in a hospital setting – infection prevention and medication safety – PRIME is developed by Joint Commission International for Patient Safety, with sponsorship by BD.

(L-R) Program logo of the PRIME program; BD & JCI representatives along with guests from leading private hospitals in the region at the PRIME launch ceremony for SEA held in Bangkok, Thailand on 24th April 2019.

Speaking about JCI’s initiation of PRIME with BD, Dr. Marwa J. Zohdy, vice president, Global Consulting Services, Joint Commission Resources/Joint Commission International (JCI) said, “The preparation and administration of medication is critical to safe, high-quality patient care around the world. At JCI, we recognize a fundamental need for evidence-based capability building on this topic, and the unique PRIME program addresses that need. Leading experts from JCI with the support of BD have created a practical curriculum that will bring critical skills to life.”

A unique programmatic approach towards patient safety will be implemented over a six-month duration, composed of goal-setting, constant progress review, tele-consultations with experts and scientific updates through webinars. Hospitals will be certified upon successful completion of the program.

Raymond Chow, vice president for Central Asia at BD said, “Administration of medication via invasive routes presents unique risks. Particularly in emerging countries, the risks may be greater due to lack of awareness, standards, assessment of skills and adoption of safe technology and practices. PRIME is set to address these very risks that are often unnoticed due to inadequate focus or knowledge of streamlined processes in medication management.”

PRIME was officially launched between 22-26 April in the following countries: South Korea, Japan, Malaysia, Thailand, Indonesia, Philippines, Vietnam and India. To date, 21 leading hospitals have signed up for the program.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com. 

Photo – https://photos.prnasia.com/prnh/20190425/2446684-1
Logo – https://photos.prnasia.com/prnh/20190425/2446684-1LOGO

This all-new Android & iOS application promotes universal mental health and wellness practices through social engagement and sharing

ADA, Michigan, April 25, 2019 /PRNewswire/ — Cosmic JUJU, the all-new mental health and wellness social media app, launches today with full public release. This launch marks the first venture into social media app promotion for Cosmic JUJU’s parent company, JOY Undiluted, LLC.

“Nearly two years ago, Kendra and I found each other with a common goal of making the world a better, happier, place. Since then, we’ve launched an article-based website, and as of today, our social media app,” said Linda Anderson, CASLC, CSLC, and Co-Founder of Cosmic JUJU & JOY Undiluted. “Our team is thrilled to be spreading positivity through our app, and beyond.”

About Cosmic JUJU:

Cosmic JUJU is a mental health and wellness app, which promotes happier and healthier practices for users of all ages and backgrounds.

Through article sharing, video streaming, and community-building efforts, Cosmic JUJU is building a safe-space for sharing, learning, and growing wherever users are at on their personal or professional development journey.

Download the App:

iOS: https://itunes.apple.com/us/app/cosmic-juju/id1459630388?ls=1&mt=8 
Android: https://play.google.com/store/apps/details?id=uk.co.disciplemedia.joyundiluted

Contacts:

Kendra McComb: kmccomb@joyundiluted.com /// 844-217-8444

Logo – https://mma.prnewswire.com/media/876841/Cosmic_JUJU_Logo.jpg

UPPSALA, Sweden, April 24, 2019 /PRNewswire/ — Researchers of the Erasmus University Medical Center in Rotterdam − the Netherlands, consider that the synthetic and fully resorbable TIGR® Matrix surgical mesh (Novus Scientific AB, Uppsala − Sweden) may reduce frequent risks related to the surgical repair of Sportsman’s hernia.

Inguinal disruption – also commonly referred to as Sportman’s hernia – is a group name for painful injuries in the groin area caused by repetitive strain and strenuous training. It occurs in up to 28% of high-performing athletes, and may occasionally affect non-athletes.^[1,2]

Unlike true hernias, a Sportsman’s hernia does not include the bulging of organs or fatty tissue through a hole in the weakened muscle or tendons of the abdomen.^[1]

The initial treatment of Sportman’s hernia includes physical therapy, rehabilitation programs, sometimes in combination with steroid injections.^[1]

“A treatment option for patients not responding to initial therapy is placement of a permanent mesh by minimally invasive procedure,” explained Prof. Johan Lange of the Department of Surgery at the Erasmus University MC. “Such mesh aims to support the damaged tendons and absorbs pressure during physical exercise.”

Despite the promising results and often fast resumption of sport activities by the patient after the surgical repair, there have been several reports of chronic pain and other severe side effects related to permanent mesh placement.^[3]

According to Prof. Gert-Jan Kleinrensink of the Department of Neuroscience at the Erasmus University MC, permanent, non-absorbable meshes can cause serious complications, including chronic post-operative pain. “We are very interested to evaluate whether a slowly resorbable surgical mesh, such as the TIGR® Matrix, could help prevent these issues.”

The researchers of the R.E.P.A.I.R study group, who have published around 200 peer-reviewed articles on the use of surgical meshes in various procedures, are now planning a study to investigate the usefulness of the TIGR® Matrix surgical mesh for the treatment of inguinal disruption.

About the TIGR®Matrix

TIGR®Matrix is the first long-term resorbable, 100% synthetic, surgical mesh. Its unique technology consisting of dual-stage degradation and full resorption, paired with ease of use, is a significant step forward in surgical mesh technology.

The fast-degrading part improves the mesh’ flexibility and stretchability, provides extra strength during the immediate healing phase, and gradually absorbs during the first four months. The slow-degrading part of the mesh provides optimal strength for up to nine months with complete resorption in approximately three years. TIGR®Matrix uses 100% synthetic polymers that are well documented, clinically proven, and commonly used in medical devices since the 1970s.

About Novus Scientific

Novus Scientific AB (www.novusscientific.com) develops, manufactures and markets resorbable implants that help the body’s own healing. The headquarter, research and production facilities are located in Uppsala, Sweden.

Source
[1]   Sheen AJ, et al. Br J Sports Med. 2014;48(14):1079-87.
[2]   Nam A & Brody F. J Am Coll Surg. 2008;206(1):154-64.
[3]   Doctor HG. J Minim Access Surg. 2006;2(3):110-6.

View original content to download multimedia:http://www.prnewswire.com/news-releases/can-a-novel-temporary-and-fully-resorbable-surgical-implant-improve-the-outcome-of-common-hockey-and-soccer-injuries-300837182.html

LONDON, April 24, 2019 /PRNewswire/ — Based on its recent analysis of the South African Internet of Medical Things (IOMT) market, Frost & Sullivan recognises Kardio Group with the 2019 South Africa Product Line Strategy Leadership Award. The company’s sophisticated online platform and ecosystem of integrated, connected devices as well as its impressive list of partners give it a distinct competitive edge in a complex market. Its solutions accurately predict risks and monitor non-communicable diseases (NCDs) such as hypertension, diabetes, obesity, asthma, and chronic obstructive pulmonary disease (COPD).

“The Kardio Group leverages advanced technology to offer one of the world’s most precise and advanced toolkits for monitoring and assessing NCD risk. Kardio Group excels in innovation geared toward patient home monitoring via its Kardiofit solution, as well as in-practice diagnostic, risk stratification, and disease management via its KardioPro solution,” said Nicholas Burger, Ph.D., Consultant at Frost & Sullivan. “Kardio Group partners with iHealth, a global health informatics company that designs fitness tracking and health monitoring devices, as well as with ER24, an ambulance service to assist patients with cardiovascular emergencies detected through remote monitoring.”

The company understands the need to move beyond generalised wellness and to focus on patient-centric solutions that include predictive analytics. Kardio Group’s solutions are fully automated with cloud-based storage of all health data. For instance, Kardiofit is a Bluetooth home-based monitoring solution for patients with hypertension, diabetes, asthma, and COPD that links to emergency care. KardioPro, meanwhile, is a practice-based solution that connects a suite of point-of-care (POC) devices to measure an array of vital signs with the company’s online platform.

Medical practitioners can utilise KardioPro to capture health data accurately. Captured metrics include pulse, blood pressure, stroke volume, cardiac output, and the ankle-brachial index. KardioPro also calculates and tracks body mass index, blood oxygen saturation (oximetry), and blood glucose levels. Additionally, the system allows practitioners to assess a patient’s cholesterol, HbA1c, renal function, and urine protein levels through validated POC devices. KardioPro permits physicians to visualise, analyse, and share data from their offices or while on the move, thereby improving adherence and fostering streamlined doctor-patient interactions.

“The Kardio Group designed its product portfolio to accommodate different needs and financial capacities, and it offers both software and hardware solutions to healthcare practices and individual practitioners via a subscription model,” noted Dr. Burger. “Kardio Group has plans to address mental illnesses affecting millions of South Africans, which it aims to integrate as a health focus. Currently, the company serves the private sector but intends to expand into the public sector in the next few years.”

Each year, Frost & Sullivan presents this award to the company that develops a comprehensive product line that caters to the breadth of the market it serves. The award recognises the extent to which the product line meets customer base demands, and the overall impact it has in terms of customer value and increased market share.

Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Kardio Group

About Brandmed:

Brandmed (Pty) Limited is a South African digital health healthcare company founded in 2015 with a vision to create a global people-centric, integrated, value-based, outcome inspired health ecosystem. This vision is underpinned by visionary leaders who care, simple, validated and sustainable solution driven technologies.

Brandmed is a world first in delivering a unique fully integrated end to end solution to address outcomes and value-based care for patients with chronic lifestyle and Non-Communicable- Diseases (NCDs) such as hypertension, diabetes, high cholesterol, asthma and chronic obstructive pulmonary disease.

The KardioGroup ecosystem, developed in South Africa, seamlessly integrates a combination of connected solutions across the health continuum for patients, healthcare professionals, practices and institutions, and aims to deliver personalised patient care. This is achieved through key entities of the KardioGroup ecosystem such as, KardioFit, KardioPro, KardioLife and KardioLytix.

KardioFit an automated patient disease management, engagement and monitoring suite to empower patients to actively manage their own health in an era of the quantified self and assists medical professionals to make better informed decisions based on real world experience, resulting in improved clinical outcomes and efficiencies.

KardioPro is an integrated provider/practice point of care suite allowing for real time validated and accurate wireless collection of clinical biometrics. The solution backed by accepted Global and South African Guidelines, automatically guides data interpretation, predictive risk profile analysis and diagnosis to inform standardised, personalised patient treatment and management.

KardioLife is a unique anti-inflammatory lifestyle program.

KardioLytix provides real-time actuarial analyses of all data parameters in the Brandmed ecosystem. With the data generated on unified standards and formats, KardioLytix caters for objective measurement of value-based care outcomes.

For more information go to: www.kardiogroup.com

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

Contact:

Tarini Singh
P: +91-20 6718 9725
E: Tarini.Singh@frost.com 

Logo – https://mma.prnewswire.com/media/874787/Frost_Sullivan_Kardio_Group_Logo.jpg

TAIPEI, Taiwan, April 23, 2019 /PRNewswire/ — TaiGen Biotechnology Company, Limited (“TaiGen”) announced today that Phase III trial of the combination therapy Furaprevir – Yimitasvir for the treatment of chronic hepatitis C patients has been initiated. The combination regimen of Furaprevir and Yimitasvir was developed by Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd, a joint venture established in 2016 by TaiGen Beijing and YiChang HEC ChangJiang Pharmaceuticals. Co., Ltd (HEC). The trial protocol has been approved by CDE, Center for Drug Evaluation of NMPA. Effort was put into study design to reduce trial cost and shorten trial timeline.

The kick off investigator meeting of the phase III trial was held by Dongguan HEC TaiGen on Saturday, April 20^th, in Beijing with more than 200 researchers from 43 clinical sites attending.

The study protocol is a single-arm active treatment design with historical control. It was approved by CDE in March. Three hundred sixty (360) genotype 1 patients (both cirrhotic and non-cirrhotic) will be enrolled with the primary efficacy endpoint of SVR12 (sustained virologic response at 12 weeks). SVR12 is defined as an undetectable HCV RNA level at 12 weeks after stopping antiviral treatment.

Kuo-Lung Huang, Chairman & CEO of TaiGen, indicated that current treatments of HCV in China are imported from abroad. They are expensive and placed a huge economic burden to patient and their family as well as the healthcare system. The Furaprevir – Yimitasvir combination therapy is competitive in the Greater China market. Huang explained that Dongguan HEC TaiGen managed the trial timeline actively in order to bring this novel treatment to patient in need with minimum delay.

The Completion of Phase III trial is projected in 2020. According to the agreement, TaiGen Beijing will receive two milestone payments of five-million USD each after completing phase III trial and NDA filing.

View original content:http://www.prnewswire.com/news-releases/hec-taigen-initiates-phase-iii-trial-of-combination-of-furaprevir-and-yimitasvir-for-the-treatment-of-chronic-hepatitis-c-patients-in-china-300836216.html